IP Library Granted Patent US 11,499,730
Granted Patent B2
US 11,499,730 · App. 16/273,712 · Granted Nov 15, 2022

LPS priming of stromal cells to generate LPS-specific exosome educated macrophages

Inventors: Peiman Hematti (Middleton, WI); John A. Kink (Madison, WI); Christian Capitini (Madison, WI)
Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
F24F11/30C12N5/0645C12N5/0656C12N5/0663F24F11/50C12N2501/052F24F2110/10F24F2110/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,499,730
App. No.
16/273,712
Granted
Nov 15, 2022
Kind
B2
Abstract

The disclosure relates to an ex vivo generated population of educated macrophages specific to LPS and methods of making and using such macrophages.

Claims (15)

1. A method for generating an educated macrophage, the method comprising the steps of:

isolating extracellular vesicles from a mesenchymal stem cell previously exposed to lipopolysaccharide (LPS), and

co-culturing a CD14+ cell with the extracellular vesicles in vitro until the CD14+ cell acquires an anti-inflammatory macrophage phenotype, wherein the mesenchymal stem cell is exposed to about 800 ng/ml to about 1200 ng/ml LPS.

2. The method of claim 1 , wherein the CD14+ cell and the extracellular vesicles are co-cultured for at least 2 days.

3. The method of claim 1 , wherein the mesenchymal stem cell is exposed to LPS for at least 2 hours.

4. The method of claim 1 , wherein the CD14+ cell is a macrophage.

5. The method of claim 1 , wherein the CD14+ cell is a monocyte and wherein the CD14+ monocyte and the extracellular vesicle are co-cultured for at least 5 days.

6. A population of anti-inflammatory macrophages produced by the method of claim 1 , wherein the anti-inflammatory macrophage phenotype is characterized as FLT-3L high, IL-15 high, CD73 high, CD86 low, and HLA-DR low as compared to control macrophages.

7. A method for generating an educated monocyte, the method comprising the steps of:

isolating extracellular vesicles from a mesenchymal stem cell previously exposed to lipopolysaccharide (LPS), and

co-culturing a CD14+ monocyte with the extracellular vesicles in vitro until the CD14+ monocyte acquires an anti-inflammatory monocyte phenotype, wherein the mesenchymal stem cell is exposed to about 800 ng/ml to about 1200 ng/ml LPS.

8. The method of claim 7 , wherein the CD14+ monocyte and the extracellular vesicles are co-cultured for at least 2 hours.

9. The method of claim 8 , wherein the CD14+ monocyte and the extracellular vesicles are co-cultured for at least 24 hours.

10. The method of claim 7 , wherein the mesenchymal stem cell is exposed to LPS for at least 12 hours.

11. A population of anti-inflammatory monocytes produced by the method of claim 7 , wherein the anti-inflammatory monocyte phenotype is characterized as PD-L1 high, CD206 low, CD163 low, IL-15 high, CD73 high, CD86 low, CD16 low and IL-6 high as compared to control monocytes.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2022
From: CAPITINI, CHRISTIAN
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 060302/0265 →
CONFIRMATORY LICENSE Recorded Sep 20, 2021
From: UNIVERSITY OF WISCONSIN MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 057543/0425 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2019
From: HEMATTI, PEIMAN; KINK, JOHN
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 048317/0542 →
Continuity (2)
Provisional Application 62629479 · Feb 12, 2018
Related Publication 20190249144A1 · Aug 15, 2019